Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shot up 3.6% during mid-day trading on Friday . The stock traded as high as $12.48 and last traded at $11.79. 676,685 shares traded hands during trading, an increase of 8% from the average session volume of 627,090 shares. The stock had previously closed at $11.38.

Several research firms have recently issued reports on COLL. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Needham & Company LLC restated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Friday. Finally, Jefferies Group LLC restated a “buy” rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a research note on Friday. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.00.

The firm’s 50 day moving average is $10.53 and its 200 day moving average is $10.53. The firm’s market capitalization is $348.58 million.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $4.07 million. Analysts forecast that Collegium Pharmaceutical, Inc. will post ($3.00) earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares during the period. Voya Investment Management LLC bought a new position in Collegium Pharmaceutical during the second quarter worth about $125,000. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 16.4% during the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares during the period. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares during the period. Finally, UBS Group AG grew its holdings in Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the period. Institutional investors and hedge funds own 83.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-shares-up-3-6/1616759.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.